cbdMD (YCBD) Capital Expenditures Growth (3y) (2019 - 2025)
cbdMD (YCBD) Capital Expenditures Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.42% |
| Sep 30, 2025 | -76.87% |
| Jun 30, 2025 | -74.45% |
| Mar 31, 2025 | -52.29% |
| Dec 31, 2024 | -10.72% |
| Sep 30, 2024 | -31.00% |
| Mar 31, 2024 | -26.72% |
| Dec 31, 2023 | 25.55% |
| Sep 30, 2023 | 30.57% |
| Jun 30, 2023 | 22.72% |
| Mar 31, 2023 | -27.70% |
| Dec 31, 2022 | -31.66% |
| Sep 30, 2022 | -35.38% |
| Jun 30, 2022 | -29.95% |
| Mar 31, 2022 | 15.66% |
| Dec 31, 2021 | 185.53% |
| Sep 30, 2021 | 13.01% |
| Mar 31, 2021 | 774.27% |
| Dec 31, 2020 | 227.13% |
| Sep 30, 2020 | -322.47% |